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The Cytoprotective Effects of Human Endothelial Progenitor Cell-Conditioned 
Medium Against an Ischemic Insult Are Not Dependent on VEGF and IL-8
Stefano Di Santo, Anna-Lena Fuchs, Ramesh Periasamy, Stefanie Seiler, and Hans Rudolf Widmer
Department of Neurosurgery, Neurocenter and Regenerative Neuroscience Cluster, 
University of Bern, Inselspital, Bern, Switzerland
Endothelial progenitor cells (EPCs) promote revascularization and tissue repair mainly by paracrine actions. In the 
present study, we investigated whether EPC-secreted factors in the form of conditioned medium (EPC-CM) can 
protect cultured brain microvascular endothelial cells against an ischemic insult. Furthermore, we addressed the 
type of factors that are involved in the EPC-CM-mediated functions. For that purpose, rat brain-derived endothe-
lial cells (rBCEC4 cell line) were exposed to EPC-CM pretreated with proteolytic digestion, heat inactivation, and 
lipid extraction. Moreover, the involvement of VEGF and IL-8, as canonical angiogenic factors, was investigated 
by means of neutralizing antibodies. We demonstrated that EPC-CM significantly protected the rBCEC4 cells 
against an ischemic insult mimicked by induced oxygen–glucose deprivation followed by reoxygenation. The 
cytoprotective effect was displayed by higher viable cell numbers and reduced caspase 3/7 activity. Heat inactiva-
tion, proteolytic digestion, and lipid extraction resulted in a significantly reduced EPC-CM-dependent increase 
in rBCEC4 viability, tube formation, and survival following the ischemic challenge. Notably, VEGF and IL-8 
neutralization did not affect the actions of EPC-CM on rBCEC4 under both standard and ischemic conditions. In 
summary, our findings show that paracrine factors released by EPCs activate an angiogenic and cytoprotective 
response on brain microvascular cells and that the activity of EPC-CM relies on the concerted action of nonpro-
teinaceous and proteinaceous factors but do not directly involve VEGF and IL-8.
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INTRODUCTION
Neuronal tissue integrity is strongly dependent on 
appropriate blood perfusion. In addition to the impor-
tance of a functional vascular system under normal physi-
ological conditions, the activation of angiogenesis plays 
a crucial role in tissue regenerative processes (31,50). 
In the context of therapeutic interventions aimed at pro-
moting tissue recovery, cell transplantation represents a 
promising approach. Evidence accumulated over the last 
several years indicates that the therapeutic effect of trans-
planted stem/progenitor cells in injured tissues primarily 
relies on the secretion of paracrine factors (4,45,59). In 
fact, improved tissue functionality is typically associated 
with low levels of cell engraftment and transdifferentia-
tion (1,15). Therefore, there is a general consensus that 
stem/progenitor cells support tissue regeneration mainly 
by trophic and immunomodulatory actions (18,38). There 
are a variety of factors secreted by stem/progenitor cells, 
including growth factors, cytokines, and chemokines, a 
group of factors generally referred to as a secretome (43). 
The composition of the secretome varies depending on 
the type of stem/progenitor cells being studied (19).
Encouraging results have been obtained in preclinical 
studies and clinical trials that used endothelial progenitor 
cells (EPCs) to promote revascularization and repair of 
the ischemic heart and limbs (6,20,23,26). In line with this 
notion, successful neuronal regeneration after ische mic 
stroke by administration of EPCs has also been reported 
recently (39,46).
Exploiting tissue repair by means of paracrine factors in 
the form of cell-free therapy is a growing area of interest 
in regenerative medicine (2,5,7,29,32). We have previously 
shown that soluble factors secreted by EPCs promote angio-
genic functions in rat brain microvascular endothelial cells 
through AKT and ERK (13). Despite the progress made in 
deciphering the secretome (24,35), a clear molecular signa-
ture of the effectors of EPC-conditioned medium (EPC-CM)-
mediated angiogenesis and cytoprotection is still missing. A 
considerable number of studies reported on the identification 
of specific growth factors and cytokines as key mediators 
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of paracrine-induced activities by different stem/progenitor 
cells (30,36,42). Among these factors, the angiogenic factors 
interleukin-8 (IL-8) and vascular endothelial growth factor 
(VEGF) were identified to be crucial in attenuating injury 
and promoting recovery of damaged tissue (9,10,29,60). 
Moreover, recent studies have shown evidence that lipids 
play a key role as mediators of the paracrine actions of mes-
enchymal stem cells (MSCs) (48,54).
In the present work, we explored the cytoprotective 
capacity of EPC-CM on rat brain microvascular endothe-
lial cells using an in vitro model of ischemia. Moreover, 
we sought to further characterize the factors involved 
in the activity of EPC-CM. Thus, in the present study, 
we investigated whether the properties of EPC-CM 
rely on proteinaceous factors with special emphasis on 
the involvement of VEGF and IL-8. We also addressed 
whether lipids in EPC-CM might function as mediators 
of the paracrine actions of EPCs.
MATERIALS AND METHODS
Endothelial Cell Culture
The rat brain microvascular cell line rBCEC4 was kindly 
provided by Dr. I. Blasig (Forschungsinstitut für Molekulare 
Pharmakologie, Berlin, Germany). Cells were grown on 
1% gelatin (Bio-Rad, Cressier, Switzerland)-coated plates 
in Dulbecco’s modified Eagle medium (DMEM; Thermo 
Fisher Scientific, Reinach, Switzerland) containing 5% 
fetal bovine serum (FBS; Gibco, Reinach, Switzerland), 
1% antibiotics/antimycotics (Sigma-Aldrich, St. Louis, 
MO, USA), 1.2 mM glutamine (Invitrogen, Reinach, 
Switzerland), 100 μg/ml heparin (Sigma-Aldrich), and 
10 μg/ml endothelial cell growth factor (ECGF; Millipore, 
Temecula, CA, USA), at pH 7 in a humidified incubator 
at 37°C and 5% CO2 as previously described (13).
EPC Culture and Conditioned Medium Preparation
EPCs were isolated from peripheral blood mononuclear 
cells from healthy human anonymous donors as previously 
described (20). The buffy coats employed for mononuclear 
cell isolation were obtained from a commercial source 
(Interregional Transfusion Centre of the Swiss Red Cross, 
Bern, Switzerland) approved by the Swiss Accreditation 
Service (SPTS 003); therefore, no experimental approval 
or informed consent was further needed. Moreover, all 
samples were handled according to the regulations and 
guidelines of the University Hospital Bern. In total, 21 
buffy coats were processed for EPC cultures. While the 
identity of the donors of the buffy coats was unknown 
(the samples were anonymized), all 21 buffy coats used 
were from different lot numbers. Therefore, we assume 
that some variability between outcomes of the experiments 
was due to this circumstance. Mononuclear cells were 
isolated by gradient centrifugation using Lymphoprep 
(Axis-Shield, Dundee, UK) and cultured on six-well 
plastic dishes (BD Falcon, Allschwil, Switzerland) coated 
with human fibronectin (Sigma-Aldrich) at a density of 1 
million cells/cm2 using endothelial cell basal medium-2 
(EBM-2; Lonza, Basel, Switzerland) supplemented with 
endothelial growth medium SingleQuots (Lonza) and 5% 
FBS (Lonza). After 4 days in culture, adherent cells were 
passaged at the density of 0.1 million cells/cm2 and cul-
tured through day 7 to obtain early outgrowth EPCs. To 
produce EPC-CM, EPCs were exposed to hypoxia, since 
we have previously observed that these culture conditions 
enhance soluble factor secretion by EPCs (14). Notably, 
with the aim of limiting the effect of endogenous factors 
present in the serum, in this step a medium with reduced 
serum content was used (1% FBS). Accordingly, EPCs 
were washed three times with phosphate-buffered saline 
(PBS; Inselspital Hospital Pharmacy, Bern, Switzerland) 
and incubated in 2.5 ml growth factor-free EBM-2 contain-
ing 1% FBS for 48 h under hypoxic conditions (1.5% O2, 
5% CO2, 93.5% N2) using a humidified gas-sorted anoxic 
incubator-gloved box (InVivo2 400; Ruskinn Technologies, 
Bridgend, UK). After incubation, EPC-CM was collected 
and centrifuged at 200 × g at 4°C; the supernatant was fil-
tered under sterile conditions and snap-frozen until use 
(14). Overall, the experiments were conducted using indi-
vidual EPC-CM preparations. The EBM-2 containing 1% 
FBS was treated in parallel to the cell cultures and served 
as control medium. Throughout all of the experiments, 
EPC-CM and control medium were exposed simultane-
ously to the same treatments.
Conditioned Medium Dilution
For the dose–response experiment, immediately before 
use, EPC-CM was diluted in control medium to the final 
concentrations of 10%, 20%, and 50% (1:10, 1:5, and 
1:2, respectively).
Multiplex Assay
The concentrations of IL-8 (in eight different samples) 
and VEGF (in four different samples) were assessed in 
supernatants of EPC cultures grown for 48 h (in two inde-
pendent experiments) using a multiplex assay (Bioplex; Bio-
Rad, Cressier, Switzerland) as previously described (14).
Conditioned Medium Treatments
Heat treatment of EPC-CM was performed in order 
to denature the proteinaceous components of EPC-CM. 
Briefly, 15-ml polypropylene test tubes (BD Falcon, 
Allschwil, Switzerland) containing 6 ml of medium were 
immersed in boiling distilled water for 10 min, and then 
the tubes were transferred to ice-cold water for 5 min.
For the protease treatment, the medium was incubated 
with proteinase K immobilized on agarose beads (Sigma-
Aldrich) as described by others with minor modifications 
(48). Briefly, 3 ml of the medium was incubated with 
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agarose-proteinase K (5 U) in 15-ml polypropylene test 
tubes (BD Falcon, Allschwil, Switzerland) for 4 h at 37°C 
in a rotating roller drum. Thereafter, the tubes were centri-
fuged for 5 min at 780 × g to pellet the agarose-proteinase 
K, and the proteinase K-free supernatant was carefully 
collected and used for subsequent experiments.
Removal of lipid components from EPC-CM was 
performed by chloroform extraction (56). Briefly, equal 
volumes (6 ml) of EPC-CM and chloroform were mixed 
and centrifuged for 5 min at 1,750 × g, the aqueous phase 
was collected, and the procedure was repeated. Finally, 
the medium was transferred into an open 1-cm Petri dish, 
and the traces of chloroform were left to evaporate in the 
sterile hood for 10 min. Thereafter, the water lost during 
evaporation was reconstituted with distilled sterile water.
Viable Cell Number Assay
A PrestoBlue assay (Invitrogen) was used as previ-
ously described (13) to assess the viable cell numbers. 
Briefly, 5,000 rBCEC4 were seeded into gelatin-coated 
48-well plates and cultured as described above. After 
24 h of starvation in EBM-2 containing 1% FBS, the 
cells were then incubated with the processed EPC-CM 
for 24 h. After this period, the experimental media were 
replaced with EBM-2 containing 1% FBS and 10% 
PrestoBlue. Fluorescence readouts were acquired with a 
microplate reader (Tecan Infinite 1000, Ex. 560 nm, Em. 
590 nm; Tecan, Männedorf, Switzerland), and the values 
were corrected for the background.
In Vitro Tubular Structure Formation
The morphogenic capacity of rBCEC4 in vitro was 
investigated as previously described (57). In brief, melted 
growth factor-reduced Matrigel (Becton Dickinson AG, 
Allschwil, Switzerland) was layered in 24-well plates and 
allowed to become gelatinous. Forty thousand cells were 
resuspended in control medium, as well as the other exper-
imental culture media and seeded on the Matrigel layer. 
After 16 h of incubation, the formation of endothelial cell 
tubular structures was assessed. Digital microphotographs 
were taken at low magnification with a light microscope 
from three randomly selected fields for data analysis. The 
angiogenic response of rBCEC4 was assessed measuring 
the total length of the tubular structures with the aid of 
ImageJ software (NIH, Bethesda, MD, USA). Digitalized 
photomicrographs were slightly modified for better visu-
alization of the tubular structures.
In Vitro Ischemia–Reoxygenation
Ischemic injury (RI-I) was mimicked in vitro by exposing 
rBCEC4 to oxygen–glucose deprivation (OGD) followed 
by reoxygenation as described by others with minor modi-
fications (16,21,51). Endothelial cells were incubated in a 
glucose-free buffer (BSS0, 116 mmol/L NaCl, 1.8 mmol/L 
CaCl2, 0.8 mmol/L MgSO4, 5.4 mmol/L KCl, 1 mmol/L 
NaH2PO4, 14.7 mmol/L NaHCO3, and 10 mmol/L HEPES, 
pH 7.4; all from Merck KGaA, Darmstadt, Germany) for 
6 h in an atmosphere composed of 95% N2 and 5% CO2 
at 37°C by using a hypoxia chamber (Billups-Rothenberg 
Inc., San Diego, CA, USA). For reoxygenation, BSS0 was 
replaced with unconditioned medium or EPC-CM (either 
native or treated EPC-CM), and the cells were returned to 
standard incubation conditions (20% O2, 5% CO2, 37°C). 
As a control (Nor-Ctr), cells were incubated in a buffer 
supplemented with 5 mM of glucose (BSS5) in standard 
incubation conditions for 6 h and replaced with uncon-
ditioned medium. Cultures were kept in reoxygenation 
conditions for 3 h to measure caspase 3/7 activity or for 
18 h to assess the cell viability using PrestoBlue reagent 
(Invitrogen) as described above.
Neutralization Experiments
The blocking of IL-8 and VEGF in EPC-CM was per-
formed using specific neutralizing antibodies. In these 
experiments, EPC-CM was pretreated for 30 min at 37°C 
with anti-VEGF (goat anti-VEGF; AF 293-NA, 0.2 μg/
ml; R&D Systems Inc., Abingdon, UK) or anti-IL-8 (goat 
anti-IL-8; MAB208-NA, 2 μg/ml; R&D Systems Inc.). 
Subsequently, rBCEC4 were incubated with EPC-CM or 
the angiogenic factors in the presence or absence of the 
neutralizing antibodies.
Caspase 3/7 Activity Assay
Caspase 3 and 7 activity was measured using the 
Apo-ONE homogenous caspase 3/7 kit (Promega AG, 
Dübendorf, Switzerland). Fluorescence intensity was 
acquired with a microplate reader (Ex. 499 nm, Em. 
521 nm; Tecan Infinite 1000) as previously reported (58). 
The relative caspase 3 activity of each sample was then 
normalized to the number of viable cells in the same sam-
ple measured with PrestoBlue and expressed as percent-
age relative to the not-ischemic control group.
Statistical Analysis
For statistical analysis, a commercially available 
software package was used (Prism; GraphPad Software, 
La Jolla, CA, USA). One-way ANOVA followed by 
Bonferroni’s multiple comparison test was used to com-
pare group means. Comparisons between two groups 
were done with Welch’s t-test. Statistical significance 
was inferred at a two-sided p £ 0.05. Data are presented in 
percentage relative to the controls, and values are given 
as mean ± standard error of the mean (SEM).
RESULTS
Dose–Response Activity of EPC-CM
To assess the response of rBCEC4 to different doses 
of EPC-CM, we tested the effect of different dilutions 
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of EPC-CM on viability and tube-like formation in vitro 
(Fig. 1A and B, respectively). In line with our previous 
observations (13), viable cell numbers and tube length 
were substantially augmented by incubation with undi-
luted EPC-CM (CM100%) compared to controls (1.4-fold 
p = 0.002 and 2.4-fold p = 0.017, respectively) and steadily 
declined with increasing dilutions of EPC-CM (Fig. 1A). 
At a 20% dilution of EPC-CM (CM20%), the capacity to 
enhance cellular viability was not significantly differ-
ent from untreated controls (p = 0.48). In contrast, in the 
Figure 1. Effects of dilution of EPC-CM on viable cell number and tube length. Effects of different dilutions of the EPC-CM on viable 
cell numbers (A, n = 4) and total tubule length (B, n = 3) in rBCEC4 cultures. Note that a twofold dilution (CM50%) significantly elevated 
cell numbers (A), while up to a dilution of five times (CM20%) significantly increased tube length was detected (B). Data are presented 
as a percentage of controls, and values are given as mean + SEM. *p < 0.05 versus corresponding controls.
Figure 2. Heat and proteinase K treatments reduce viable cell number and tube length. Quantitative analyses of heating (A, n = 5; B, 
n = 4; CM-boiled) and treating the media with proteinase K treatment (C, n = 3; D, n = 4; CM-prot K) on viable cell numbers (A, C) and 
tube length (B, D) in cultures of microvascular endothelial cells. Both treatments significantly reduced the EPC-CM (CM)-mediated 
effects on number of viable cells (A, C) and total tube length (B, D). Data are presented as a percentage of controls, and values are 
given as mean + SEM. *p < 0.05 versus EPC-CM-treated cultures; #p < 0.05 versus corresponding controls.
Delivered by Ingenta to: University of Bern
IP: 130.92.9.56 On: Wed, 08 Mar 2017 13:43:36
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
PARACRINE FACTORS AND BRAIN MICROVASCULAR CELLS 739
presence of CM20%, the formation of longer tubular-like 
structures dropped to 43%, but it was still significantly 
different when compared to full EPC-CM (p = 0.0.034) 
(Fig. 1B). EPC-CM-dependent tube formation was lost at 
10% dilution (p = 0.323).
EPC-CM-Induced Activities Involve Proteinaceous 
and Heat-Labile Factors
We and others have asserted that EPCs secrete a wide 
variety of growth factors and cytokines (8,14). With the 
aim of gaining insight into the nature of the EPC paracrine 
factors, we assessed the thermostability of EPC-CM. The 
cell viability induced by native EPC-CM was completely 
abrogated by the heat treatment (p = 0.008) (Fig. 2A), 
whereas the total tube length was reduced by 44% 
(p = 0.0004) (Figs. 2B and 3). Accordingly, proteinase K 
treatment of EPC-CM (CM prot K) resulted in a signifi-
cant reduction in cell viability (18%, p = 0.049) (Fig. 2C) 
and tubular structure length (42%, p = 0.032) (Figs. 2D 
and 3) compared with untreated EPC-CM.
EPC-CM Exerts Cytoprotection Against In Vitro 
Ischemia Reoxygenation
In view of a potential use of EPC-CM for tissue regen-
eration, we assessed whether EPC-CM promotes the via-
bility of brain microvascular endothelial cells challenged 
by the detrimental effects of ischemia–reoxygenation 
(Fig. 4). Exposure of rBCEC4 to RI-I significantly 
reduced the cell viability to 58% compared to controls 
treated with unconditioned medium during the reoxy-
genation phase (p = 0.003; RI-I-Ctr) (Fig. 4A, C). This 
decline was significantly attenuated by 71% when the 
reoxygenation was carried out in the presence of EPC-CM 
(p = 0.008; RI-I-CM) (Fig. 4A, C). RI-I also induced an 
increase in caspase 3/7 activity in the cultures (1.9-fold 
relative to controls, p = 0.0016), which was significantly 
attenuated in the presence of EPC-CM (1.2-fold relative 
to controls, p = 0.0002) (Fig. 4B, D). Similar to the out-
come observed under standard conditions, both heat and 
proteinase K treatment caused significant reduction of the 
cytoprotective properties of EPC-CM with cell viability 
reaching almost the level of untreated ischemic cultures 
(p = 0.008 and p = 0.003) (Fig. 4A and C, respectively). 
Correspondingly, the activity of caspase 3/7 increased by 
40% and 38% in the cultures incubated with heat- and 
proteinase K-treated EPC-CM (RI-I-CM-boiled
 
and RI-I-
CM-prot K; p = 0.0002 and p = 0.024) (Fig. 4B and D, 
respectively) compared to native EPC-CM.
EPC-CM-Induced rBCEC4 Angiogenic Response 
Is Not Directly IL-8 and VEGF Dependent
The results described above support the view that growth 
factors and/or cytokines are involved in the EPC-CM-
induced effects. In agreement with previous observations 
Figure 3. Heat and proteinase K treatments reduce EPC-CM-induced tubular network formation. Representative microphotographs 
of tubular network formation by microvascular endothelial cells on growth factor-reduced Matrigel. EPC-CM incubation (CM) strik-
ingly promoted the tube-like structure formation compared to control medium (Ctr). Supplementation of EPC-CM, which underwent 
heat treatment (CM-boiled), substantially attenuated EPC-CM-induced tube formation. Similarly, proteinase K treatment (CM-prot K) 
resulted in a decrease of tube formation capacity. Scale bar: 100 μm.
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(13,14), the quantitative analysis of EPC-CM disclosed 
the presence of high levels of IL-8 (7,089 ± 2,637 pg/ml) 
and lower levels of VEGF (49.8 ± 21.7 pg/ml). Therefore, 
we investigated, in greater detail, the contribution of IL-8 
and VEGF to the protective effects of EPC-CM.
We first performed experiments to assess the validity of 
the experimental setup based on neutralizing antibodies. 
As expected, VEGF and IL-8 supplementation promoted 
rBCEC4 viability in a dose-dependent manner, reach-
ing a maximal effect at the concentration of 50 ng/ml for 
VEGF and 100 ng/ml for IL-8 (1.9- and 1.6-fold increase 
relative to untreated controls, respectively, p = 0.0001 and 
p = 0.009, respectively) (Fig. 5A, B). The tube formation 
capacity was likewise enhanced by 100 ng/ml VEGF and 
by 50 ng/ml IL-8 (1.6- and 1.8-fold increase relative to 
untreated controls, respectively, p = 0.005 and p = 0.0001, 
respectively) (Fig. 6A, B). These effects were abrogated 
by administration of the respective neutralizing antibod-
ies (p = 0.006 for VEGF and p = 0.0005 for IL-8) (Fig. 6). 
Importantly, however, both anti-VEGF and anti-IL-8 anti-
body treatment did not significantly affect the increase in 
rBCEC4 viability (p = 0.73 and p = 0.92) (Fig. 7A, C) nor 
tube formation (p = 0.68 and p = 0.18) (Fig. 7B, D) induced 
by EPC-CM. Similar observations were made when cul-
tures were exposed to RI-I (Fig. 8). Thus, neutralization 
of VEGF and IL-8 in EPC-CM did not affect the EPC-
CM-induced cytoprotection with regard to cell viability 
(RI-I-CM-anti-VEGF and RI-I-CM-anti-IL-8, 74% and 
79%, respectively, compared to control ischemic cultures, 
p = 0.85 and p = 0.51) (Fig. 8A) and nor the levels of cas-
pase 3/7 activity (1.4-fold increase for both compared to 
control ischemic cultures, p = 0.99 for RI-I-CM vs. RI-I-
CM-anti-VEGF and p = 0.91 for RI-I-CM vs. RI-I-CM-
anti-IL-8) (Fig. 8B).
Lipid Extraction From EPC-CM
Similar to the outcome seen for heat and proteinase K 
treatment, lipid extraction of EPC-CM diminished EPC- 
CM-mediated effects (Figs. 9–11). Lipid extraction (CM- 
chlorof) caused a slight, but significant, reduction of cell 
viability (from 1.5- to 1.2-fold increase relative to untreated 
controls, p = 0.0002) (Fig. 9A). Chloroform treatment 
Figure 4. Heat and proteinase K treatments reduce EPC-CM-mediated cytoprotection against an ischemia–reoxygenation insult. 
Quantitative analyses of heat (A, n = 4–5; B, n = 3; boiled) and proteinase K treatment (C, n = 4; D, n = 4; prot K) of the media on viable 
cell numbers (A, C) and caspase 3/7 activity (B, D) in cultures of microvascular endothelial cells exposed to a RI-I. While treatment 
with EPC-CM (CM) exerted cytoprotective effects on cell viability (A, C) and significantly reduced the augmented caspase 3/7 activ-
ity induced by the RI-I, both heat (CM-boiled) and proteinase K treatment (CM-prot K) significantly reduced the effects of EPC-CM 
(CM). Data are presented as a percentage of controls, and values are given as mean + SEM. *p < 0.05 versus corresponding EPC-CM-
treated cultures.
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triggered a reduction of 26% in the total tube length com-
pared to untreated EPC-CM (p = 0.03) (Figs. 9B and 10).
Moreover, lipid extraction by chloroform also signifi-
cantly impaired the cytoprotective capacity of EPC-CM 
displayed by a reduced viability (18% decline compared 
to native EPC-CM, p = 0.004) (Fig. 11A), paralleled by 
an increase in caspase 3/7 activity (38% rise compared to 
native EPC-CM, p = 0.02) (Fig. 11B).
DISCUSSION
In the present study, we describe that the soluble fac-
tors secreted by EPCs enhanced brain microvascular 
Figure 5. VEGF and IL-8 promote viable cell number. Dose–response analysis of vascular endothelial growth factor (VEGF; A, 
n = 3–5) and interleukin-8 (IL-8; B, n = 3–5) on viable cell numbers in cultures of microvascular endothelial cells in the absence (open 
bars) or presence of neutralizing antibodies (gray bars) against VEGF (anti-VEGF; A) and IL-8 (anti-IL-8; B). Data are presented as a 
percentage of corresponding controls, and values are given as mean + SEM. *p < 0.05 versus corresponding controls.
Figure 6. VEGF and IL-8 promote tubular structure. Effects of vascular endothelial growth factor (VEGF; A, n = 4–6) and interleukin-8 
(IL-8; B, n = 5) administration on total tube length in cultures of microvascular endothelial cells in the absence (gray bars) or presence 
of neutralizing antibodies (dark gray bars) against VEGF (anti-VEGF; A) and IL-8 (anti-IL-8; B). The significant increase in tube length 
induced by the growth factor treatment was abolished in the presence of the neutralizing antibodies. Data are presented as a percentage of 
corresponding controls, and values are given as mean + SEM. *p < 0.05 versus corresponding growth factor-treated cultures.
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Figure 7. Neutralizing antibodies do not alter EPC-CM-induced effects. Effects of neutralizing antibodies against vascular endothelial 
growth factor (CM-anti-VEGF; A, n = 5; B, n = 4) and interleukin-8 (CM-anti-IL-8; C, n = 5; D, n = 3) on viable cell numbers (A, C) and 
total tube length (B, D) in cultures of microvascular endothelial cells exposed to EPC-CM (CM). Untreated cultures served as controls 
(open bars). The significant increase in viable cell numbers (A, C) and total tube length (B, D) induced by EPC-CM (filled bars) was 
not altered by the presence of neutralizing antibodies (gray bars). Data are presented as a percentage of corresponding controls, and 
values are given as mean + SEM. *p < 0.05 versus corresponding controls.
Figure 8. VEGF and IL-8 neutralization does not alter cytoprotection induced by EPC-CM against an ischemia–reoxygenation insult. 
Quantitative analyses of neutralizing antibodies against vascular endothelial growth factor (anti-VEGF) and interleukin-8 (anti-IL-8) on 
viable cell numbers (A, n = 6) and caspase 3/7 activity (B, n = 4) in cultures of microvascular endothelial cells exposed to an RI-I. While 
treatment with EPC-CM (CM, filled bars) exerted cytoprotective effects on cell viability (A) and significantly reduced the augmented 
caspase 3/7 activity induced by the RI-I, the presence of neutralizing antibodies (gray bars) did not alter the EPC-CM-mediated effects. 
Data are presented as a percentage of untreated controls, and values are given as mean + SEM. *p < 0.05 versus corresponding controls.
Delivered by Ingenta to: University of Bern
IP: 130.92.9.56 On: Wed, 08 Mar 2017 13:43:36
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
PARACRINE FACTORS AND BRAIN MICROVASCULAR CELLS 743
Figure 9. Lipid extraction attenuates the effects of EPC-CM. Quantitative analyses of the lipid content in EPC-CM-mediated effects on 
viable cell numbers (A, n = 6) and total tube length (B, n = 4) in cultures of microvascular endothelial cells. While chloroform extraction 
(Ctr-chlorof) had no effects on control media-treated cultures (gray bars), EPC-CM (CM; filled bars) induced an increase in viable cell 
numbers, and total tube length was significantly decreased (CM-chlorof; dark gray bars). Data are presented as a percentage of controls, 
and values are given as mean + SEM. *p < 0.05 versus corresponding EPC-CM-treated cultures; #p < 0.05 versus corresponding controls.
Figure 10. Lipid extraction reduces EPC-CM-induced tubular network formation. Representative digital microphotographs of tubular 
network formation by microvascular endothelial cells on growth factor-reduced Matrigel. EPC-CM incubation (CM) robustly pro-
moted the tube-like structure formation compared to control medium (Ctr). Lipid extraction of the EPC-CM (CM-chlorof) significantly 
attenuated EPC-CM-induced tube formation. Scale bar: 100 μm.
Figure 11. Lipid extraction reduces EPC-CM-mediated cytoprotection against an RI-I. Quantitative analyses of the lipid content in 
EPC-CM-mediated effects on viable cell numbers (A, n = 4) and caspase 3/7 activity (B, n = 5) in cultures of microvascular endothelial 
cells exposed to an RI-I. Treatment with EPC-CM (CM; filled bars) exerted cytoprotective effects on cell viability and significantly 
reduced the augmented caspase 3/7 activity induced by the RI-I. Chloroform extraction (CM-chlorof; gray bars) was found to abolish 
the EPC-CM-induced effects on cell viability and caspase 3/7 activity. Data are presented as a percentage of untreated controls, and 
values are given as mean + SEM. *p < 0.05 versus corresponding EPC-CM-treated cultures.
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endothelial cell growth, tube formation capacity, and cell 
survival in an oxygen–glucose deprivation (RI-I) culture 
model that mimics the acute ischemic stroke situation 
in humans. These findings further support the cytopro-
tective properties of EPCs against ischemic insults in 
various organs and tissues including the brain vascular 
cells (28,46,52). We provide evidence that the paracrine 
actions of EPC-CM are mediated by thermo-labile, pro-
tease-sensitive, as well as chloroform-extractable factors. 
Moreover, our data suggest that VEGF and IL-8 might 
not directly contribute to the effects of EPC-CM.
It is now a widely accepted opinion that paracrine 
actions of stem/progenitor cells are the major player in tis-
sue protection/repair (53). Despite the critical importance 
of this aspect of regenerative medicine, the molecular 
effectors and the mechanisms of action of EPC-paracrine 
factors are still elusive. Consequently, great emphasis has 
been given to the need for dissection of the entire spec-
trum of growth factors and cytokines secreted by EPCs. 
In this line, in the present work, we initially aimed at veri-
fying whether the effects of EPC-CM rely solely on pro-
teins. Indeed, the observed susceptibility of EPC-CM to 
heat and to protease treatment implies that proteinaceous 
factors contribute, at least in part, to the cytoprotective 
and proangiogenic properties of EPC-CM.
In order identify the potential factors involved in the 
enhanced endothelial survival, tubular structure forma-
tion, and protection against an ischemic insult, we focused 
our attention on IL-8 and VEGF. These two factors were 
selected out of several growth factors and cytokines found 
to be secreted by EPCs, since they have been described as 
master regulators of endothelial cell survival and vascu-
lar growth (33,40). In the present work, quantitative mea-
surements of IL-8 and VEGF as well as the dose–response 
analysis using the recombinant peptides indicate that the 
concentration of VEGF and IL-8 found in EPC-CM is 
at subthreshold level. This observation combined with 
our previous findings that IL-8 is among the angiogenic 
factors found in EPC-CM in highest concentration (13) 
suggests that the effects of EPC-CM rely on mechanisms 
different from the canonical response to single factor 
treatment. It should also be considered that the cultures 
exposed to EPC-CM might display an altered sensitivity 
to growth factors compared to untreated controls. In fact, 
effects of potentiation of growth factor activity might 
occur possibly as a result of synergic actions of multiple 
factors contained in EPC-CM (57).
In control experiments, the activity of the recombi-
nant IL-8 and VEGF could be effectively blocked by 
neutralizing antibodies, whereas these failed to attenuate 
the EPC-CM-induced effects. In light of these in vitro 
results, we concluded that, taken individually, IL-8 and 
VEGF appear to not be major players of the EPC-CM-
enhanced viability, tubulogenesis, and protection from 
the ischemia–reperfusion damage. However, it cannot 
be excluded that the lack of blockade of IL-8 and VEGF 
could result from the presence of splice variants or redun-
dant growth factors structurally and functionally related to 
these two. Importantly, these findings replicate our previ-
ous observations showing that the antiapoptotic response 
promoted by EPC-CM was not diminished by individual 
or collective neutralization of VEGF, hepatocyte growth 
factor (HGF), matrix metalloproteinase-9 (MMP-9), and 
IL-8 (58). In contrast, other reports have shown signifi-
cant reduction of the angiogenic properties of myeloid 
angiogenic cells and late (outgrowth) EPCs by blocking 
IL-8 (17,33). The reasons underlying these discrepancies 
remains to be investigated and could be, in part, due to 
the different experimental systems employed, such as 
the use of a different type of endothelial cells to test the 
angiogenic functions of EPC-CM or a different method of 
EPC-CM production. In the present study, we employed 
EPC-CM produced in hypoxic cultures, since it has been 
demonstrated that low oxygen promotes the angiogenic 
properties of EPCs (22). This is consistent with enhanced 
release of proangiogenic factors in EPCs exposed to low 
oxygen tension (14,27). Additionally, hypoxia as well as 
tissue ischemia have been shown to promote EPC mobi-
lization and tissue revascularization thereby augmenting 
the therapeutic capacity of transplanted cells (34,55).
The observations that heat and proteinase K treatment 
of EPC-CM significantly lowered, but not completely 
abolished, the effects EPC-CM in brain endothelial cells 
imply that the EPC-CM-dependent endothelial cell via-
bility and tubulogenesis might be mediated by proteina-
ceous as well as nonproteinaceous factors. Indeed, the 
inhibitory effect of chloroform extraction on EPC-CM 
activity suggests that lipids are one group of bioactive 
factors contained in EPC-CM, which might act in concert 
with growth factors and cytokines to promote the func-
tions of microvascular endothelial cells.
Despite the growing attention given to the lipids 
released by stem cells as paracrine mediators (25,48), the 
involvement of lipids released by EPCs has not been thor-
oughly investigated so far. In fact, the findings that EPCs 
secrete signaling lipids such as prostanoids and endocan-
nabinoids (11,37) further underscore the potential of EPCs 
as vascular and neuronal therapeutics. Also, shingosine-
1-phosphate seems to play a pivotal role in endothelial 
autocrine/paracrine cross talk and is a potent regulator of 
different vascular functions (41,47). In the present work, 
the specific identity of the lipids that might be involved 
in the enhanced tube formation and increased cell survival 
under ischemic conditions in vitro was not addressed. In 
particular, whether the chloroform-extractable factor(s) in 
EPC-CM are freely soluble lipids or consist of exosomes 
or as moieties of lipid-modified proteins, such members of 
the Wnt family [e.g., Wnt 5a (3)] remains to be investigated. 
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Our findings showing that both proteinaceous factors and 
lipids play a role in the EPC-CM-mediated actions may 
hint at the idea that these effects involved released exo-
somes or microvesicles. It has been reported that exosomes 
and microvesicles are involved in many types of cell–cell 
communication, being able to shuttle virtually all kinds of 
signaling molecules, including proteins, lipids, and RNA 
(12,44). Nevertheless, we did not perform experiments that 
would prove such an assumption, and follow up studies are 
needed to investigate the role of exosomes in EPC-CM-
mediated protection and the possible interplay between 
proteinaceous factors and lipids, all of which represent 
important aspects of the paracrine signaling that indeed 
deserve deeper analysis (49).
In conclusion, we provide the evidence that EPC-CM 
promotes endothelial cell survival, tube-formation capac-
ity, and survival in an in vitro model of ischemia, likely 
through a combination of factors of a proteinaceous and 
lipidic nature. Overall, these results complement the 
known cytoprotective and angiogenic functions of EPC-
derived soluble factors (13,22). It is important to note, 
while stressing again the vast complexity of composition 
of the factors released by EPCs, the findings described 
here encourage verification through in vivo studies. 
Insights into the in vivo translation of mechanisms of 
action of EPC-CM are hence mandatory and fundamen-
tal to enable the development of therapeutic interventions 
based on paracrine factors.
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